Background
Methods
Results
Demographic characteristics of the study populations reviewed
Study
|
Age range
|
Mean age
|
Sex
|
Race
|
Proportion of sample with schizophrenia and bipolar disorder
|
Antipsychotic use
|
---|---|---|---|---|---|---|
Kilbourne, 2011 [22] | 18-65 | 55 | 9% female | 24% black, | 100% Schizophrenia | 100% |
76% other | ||||||
Morrato, 2008 [25] | All ages | Not reported | 50% female | 58% white, | 100% Schizophrenia1 | 100% |
42% other | ||||||
Moeller, 2011 [26] | 18-64 | 44 | 49% female | 83% white, | 100% Schizophrenia | 100% |
17% other | ||||||
Morrato, 2009 [27] | 20-88 | Not reported | 50% female | Not reported | 3.4% Schizophrenia, 49.3% Mood disorders, including bipolar disorder | 100% |
Kaplowitz, 2006 [30] | 20+ | 67 | 4% female | Not reported | 51.0% Mood disorders, including bipolar disorder | Not reported |
Weissman, 2006 [31] | 18-65 | 50 | 6% female | Not reported | 100% Schizophrenia | 100% |
Barnett, 2010 [32] | 21-63 | 45 | 59% female | 43% white, | Not reported | 100% |
14% black, | ||||||
43% other | ||||||
Kilbourne, 2008 [34] | 18+ | 67 | 3% female | 8% black, | 100% Schizophrenia, bipolar disorder, or other psychosis2 | Not reported |
92% other | ||||||
Folsom, 2002 [35] | 45+ | 51 | 47% female | 70% white, | 100% Schizophrenia3 | Not reported |
15% black, | ||||||
15% other | ||||||
Dickerson 2003 [38] | 18-65 | 44 | 53% female | 56% white, | 50% Schizophrenia, 25% Bipolar disorder | Not reported |
35.5% black, | ||||||
8.5% other |
Overweight and obesity (Panel 1)
Study population
|
Main finding in words
|
References
|
---|---|---|
Panel 1: Screening for Overweight and Obesity
| ||
Body Mass Index
| ||
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Outpatient Veterans participating in the National Psychosis Registry, | Screening year(s): 2007 | Time window for ascertaining screening rate: Bi-annual | Data source: Administrative claims | 76% of patients had Body Mass Index (BMI) assessed in 2007 | Kilbourne, 2011 [22] |
Panel 2: Screening for Diabetes Mellitus
| ||
Glucose screening
| ||
N: 55436 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and Outpatient Medicaid beneficiaries from California, Oregon, Tennessee and Utah | Screening year(s): 1998–2003 | Time window for ascertaining screening rate: 14 days prior-28 days after second generation antipsychotic initiation | Data source: Administrative claims | 18% of those without schizophrenia and 23% of those with schizophrenia had a glucose test during 1998-2003 | Morrato, 2008 [25] |
Compared to those without schizophrenia, those with schizophrenia had 1.5 times greater odds of having a glucose test during 1998–2003 (p < .05) | ||
N: 18876 | % of study sample with schizophrenia or bipolar disorder: 3.4% schizophrenia and 49.3% mood disorders, including bipolar disorder | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient commercial health insurance beneficiaries | Screening year(s): 2001–2006 | Time window for ascertaining screening rate: 30 days prior-30 days after second generation antipsychotic initiation | Data source: Administrative claims | The mean glucose testing rate for antipsychotic-treated patients was 23% during 2001-2006 | Morrato, 2009 [27] |
N: 2204 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid beneficiaries | Screening year(s): 2003 | Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 23% of patients had a glucose test during 2002-2003 | Moeller, 2011 [26] |
29% of patients with dyslipidemia had a glucose test during 2002-2003 | ||
N: 1646| % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid beneficiaries| Screening year(s): 2005-2007| Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 75% of patients had a glucose test during 2005-2007 | |
65% of patients with dyslipidemia had a glucose test during 2005-2007 | ||
N: 6601 | % of study sample with schizophrenia or bipolar disorder: Not reported | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient California Medicaid recipients | Screening year(s): 2004-2005| Time window for ascertaining screening rate: Six months prior to-6 months after second generation antipsychotic initiation| Data source: Administrative claims | 24% of patients had a glucose test in the six months prior to antipsychotic initiation during 2004-2005 | Barnett, 2010 [32] |
28% of patients had a glucose test in the six months after antipsychotic initiation during 2004-2005 | ||
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Outpatient Veterans participating in the National Psychosis Registry | Screening year(s): 2007 | Time window for ascertaining screening rate: Bi-annual | Data source: Administrative claims | 60% of patients had at least two glucose tests in 2007 | Kilbourne, 2011 [22] |
Glucose and Lipids Screening
| ||
N: 6601 | % of study sample with schizophrenia or bipolar disorder: Not reported | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient California Medicaid recipients | Screening year(s): 2004–2005 | Time window for ascertaining screening rate: Six months prior-6 months after second generation antipsychotic initiation| Data source: Administrative claims | 23% of patients had both a glucose test and a lipid test in the six months prior to antipsychotic initiation during 2004-2005 | Barnett, 2010 [32] |
27% of patients had both a glucose test and a lipid test in the six months after antipsychotic initiation during 2004-2005 | ||
Panel 3: Screening for Dyslipidemia
| ||
Any Lipid Screening
| ||
N: 200 | % of study sample with schizophrenia or bipolar disorder: 75% | Percent antipsychotic users: Not reported | Study population: Outpatients from psychiatric care centers in Baltimore, MD | Screening year(s): 2000 | Time window for ascertaining screening rate: Annual| Data source: Interview data | In 2000, 51% of patients reported having had their cholesterol checked in the past year | Dickerson 2003 [38] |
N: 55436 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and Outpatient Medicaid beneficiaries from California, Oregon, Tennessee and Utah | Screening year(s): 1998–2003 | Time window for ascertaining screening rate: 14 days prior-28 days after second generation antipsychotic initiation | Data source: Administrative claims | 6% of those without schizophrenia and 9% of those with schizophrenia had a lipid test during 1998-2003 | Morrato, 2008 [25] |
Compared to those without schizophrenia, those with schizophrenia had 1.4 times greater odds of having a lipid test during 1998–2003 (p < .05) | ||
N: 94 | % of study sample with schizophrenia or bipolar disorder: 100% Percent antipsychotic users: Not reported | Study population: Outpatient homeless shelter clinic users | Screening year(s): 1999–2000 | Time window for ascertaining screening rate: Annual | Data source: Medical chart review | 55% of those with schizophrenia had a lipid test during 1999-2000 | Folsom, 2002 [35] |
N: 408 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Veterans | Screening year(s): 1999–2003 | Time window for ascertaining screening rate: Four years | Data source: Administrative claims | 85% of patients had at least one lipid test during 1999-2003 | Weissman, 2006 [31] |
27% of patients had only one lipid test during 1999-2003 | ||
N: 64,490 | % of study sample with schizophrenia or bipolar disorder: 51% mood disorders, including bipolar disorder| Percent antipsychotic users: Not reported | Study population: Outpatient Veterans from New England Health Care System | Screening year(s): 2000–2001 | Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 85% of patients with mental illness had a lipid test, compared to 78% of patients without mental illness in 2001 | Kaplowitz, 2006 [30] |
Compared to those without SMI, those with SMI had 2.73 times greater odds of having a lipid test in 2001 (p < .05) | ||
N: 18876 | % of study sample with schizophrenia or bipolar disorder: 3.4% schizophrenia, 49.3% mood disorders, including bipolar disorder| Percent antipsychotic users: 100% | Study population: Inpatient and outpatient commercial health insurance beneficiaries | Screening year(s): 2001–2006 | Time window for ascertaining screening rate: 30 days prior-30 days after second generation antipsychotic initiation | Data source: Administrative claims | The mean lipid testing rate for antipsychotic-treated patients was 8% during 2001-2006 | Morrato, 2009 [27] |
N: 2204| % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid beneficiaries | Screening year(s): 2003| Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 10% of patients had a lipid test during 2002-2003 | Moeller, 2011 [26] |
N: 1646| Diagnoses: Schizophrenia | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid beneficiaries | Screening year(s): 2005–2007 | Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 53% of patients had a lipid test during 2005-2007 | |
N: 6601 | % of study sample with schizophrenia or bipolar disorder: Not reported| Percent antipsychotic users: 100% | Study population: Inpatient and outpatient California Medicaid recipients | Screening year(s): 2004–2005 | Time window for ascertaining screening rate: Six months prior-6 months after second generation antipsychotic initiation | Data source: Administrative claims | 39% of patients had a lipid test in the six months prior to antipsychotic initiation during 2004-2005 | Barnett, 2010 [32] |
43% of patients had a lipid test in the six months after antipsychotic initiation during 2004-2005 | ||
N: 46,430 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: Not reported | Study population: Inpatient or outpatient veterans with hyperlipidemia participating in National Psychosis Registry | Screening year(s): 2005 | Time window for ascertaining screening rate: Annual | Data source: Medical chart review | 90% of those with SMI, 94% of those with depression, and 94% of those without a psychiatric disorder had a lipid test in 2005 (p < .001) | Kilbourne, 2008 [34] |
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% |Percent antipsychotic users: 100% | Study population: Outpatient Veterans participating in the National Psychosis Registry| Screening year(s): 2007 | Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 37% of patients had a lipid test in 2007 | Kilbourne, 2011 [22] |
Low Density Lipoprotein (LDL) Screening
| ||
N: 408 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Veterans | Screening year(s): 1999–2003 | Time window for ascertaining screening rate: four years| Data source: Administrative claims | 74% of patients had at least one LDL test during 1999-2003 | Weissman, 2006 [31] |
28% of patients had only one LDL test during 1999-2003 | ||
Triglyceride Screening
| ||
N: 408 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent antipsychotic users: 100% | Study population: Inpatient and outpatient Veterans | Screening year(s): 1999–2003 | Time window for ascertaining screening rate: four years | Data source: Administrative claims | 85% of patients had at least one triglycerides test during 1999-2003 | Weissman, 2006 [31] |
27% of patients had only one triglycerides test during 1999-2003 | ||
Panel 4: Screening for Hypertension
| ||
Any Blood Pressure Assessment
| ||
N: 200 | % of study sample with schizophrenia or bipolar disorder: 75%| Percent antipsychotic users: Not reported | Study population: Outpatients from psychiatric care centers in Baltimore, MD | Screening year(s): 2000 | Time window for ascertaining screening rate: Annual| Data source: Interview data | In 2000, 88% of patients reported having had their blood pressure checked in the past year | Dickerson 2003 [38] |
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% |Percent antipsychotic users: 100% | Study population: Outpatient Veterans participating in the National Psychosis Registry | Screening year(s): 2007 | Time window for ascertaining screening rate: Annual | Data source: Administrative claims | 79% of patients had blood pressure assessed in 2007 | Kilbourne, 2011 [22] |
USPSTF recommendation
[
13
]
|
Studies (N)
|
Measures abstracted(N)
|
Population with SMI
|
Overall population
|
---|---|---|---|---|
Range in screening rates
|
National estimates of percent screened
| |||
Panel 1: Screening for Overweight and Obesity
| ||||
Screening all adults for obesity | 1 | 1 | Screening rate: 76% [22] Screening year: 2007 | |
Panel 2: Screening for Diabetes
| ||||
Screening for type 2 diabetes in asymptomatic adults with sustained blood pressure greater than 135/80 mmHg | 5 | 10 | Lowest screening rate: 23% [25] Screening year(s): 1998-2003 | National estimates: 94% [29] (2005–2007) |
Highest screening rate: 75% [26] Screening year(s): 2005-2007 | ||||
Panel 3: Screening for Dyslipidemia
| ||||
Screening for lipid disorders (Men: aged 35+; or 20-35+ if at increased risk for coronary heart disease; Women: aged 20+ if at increased risk for coronary heart disease) | 10 | 17 | Lowest screening rate: 6% [25] Screening year(s): 1998-2003 | |
Highest screening rate: 90% [34] Screening year(s): 2005 | ||||
Panel 4: Screening for Hypertension
| ||||
Screening for high blood pressure in adults | 2 | 2 | Lowest screening rate: 79% [54] Screening year(s): 2007 | |
Highest screening rate: 88% [38] Screening year(s): 2000 |